Drug intelligence / Profile preview

APH01727

Development stage: Unknown
Lead developer: Apichope Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

APH01727 is an oral GLP-1 receptor agonist being developed by Guangzhou Yipinhong Pharmaceutical (also known as Eden-Pharma) for the treatment of type 2 diabetes mellitus and weight management. It is designed to mimic the physiological effects of the incretin hormone GLP-1, which includes enhancing glucose-dependent insulin secretion, reducing glucagon levels, and promoting satiety. The drug is currently undergoing Phase 1 clinical trials in China to evaluate its safety, tolerability, and pharmacokinetic profile in healthy volunteers, including assessments of food effects on absorption.

Targets

GLP1R (GLP-1R)

Beyond the preview

Go deeper on APH01727.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on APH01727.

Explore the full profile